TB prevention study for children with and without HIV
Treatments studied
Part of Infections clinical trials.
This study tests a daily combination of two medicines, rifapentine and isoniazid, to prevent tuberculosis (TB) in children under 13 years old. It aims to see if this short treatment is safe and works well for kids, including those living with HIV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be under 13 years old.
- Your child must weigh between 3 kg and 45 kg (about 6.6 to 99 pounds).
- Your child must be at risk for TB, such as being in close contact with someone who has TB or having a positive TB test.
- Your child must have normal or mildly abnormal liver, kidney, and blood test results.
- Your child must not have active TB or have been exposed to drug-resistant TB.
- Your child must not have taken certain TB medicines recently, and must not have certain medical conditions like hepatitis or allergies to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a shorter course of tuberculosis (TB) medicine works as well as the current longer treatment for children. If successful, it means fewer days of medicine and fewer side effects for kids.
This trial tests a shorter treatment for children with tuberculosis (TB) that is not drug-resistant. It aims to find out if a shorter regimen works as well as the standard longer one, making treatment easier for children and their families.
This study tests different treatment plans for people with tuberculosis (TB) that can be cured with standard medicines. It aims to find the best treatment for each person based on their risk score, which may lead to shorter or more effective treatment.
This trial tests if a short course of medication can prevent tuberculosis (TB) in children and teenagers who have been in close contact with someone who has active TB. The goal is to see if this approach can stop them from developing the disease.
This study tests a home-based approach to giving tuberculosis (TB) preventive treatment to children who live with someone recently diagnosed with TB. The goal is to make it easier for families to protect children from getting sick with TB.
This Phase 2 study tests MTBVAC, a TB vaccine candidate, to see if it is safe and whether it helps the immune system. It may be a fit if you’re eligible for TB and HIV-related vaccine safety testing and can follow study visits and testing.
Hear when a new Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.